Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis

被引：2

作者：

Wei, Chenyu ^{[1
]}

Du, Xuelin ^{[2
]}

Hu, Jiexuan ^{[1
]}

Dong, Yin ^{[1
]}

Chen, Yan ^{[3
]}

Cao, Bangwei ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China

[2] Capital Med Univ, Beijing Friendship Hosp, Clin Trial Inst, Beijing 100050, Peoples R China

[3] Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 198卷

基金：

中国国家自然科学基金;

关键词：

Gastric cancer; Perioperative chemotherapy; Neoadjuvant chemotherapy; Meta; -analysis; MULTICENTER PHASE-III; NEOADJUVANT CHEMOTHERAPY; D2; GASTRECTOMY; OPEN-LABEL; CAPECITABINE; OXALIPLATIN; CISPLATIN; ADENOCARCINOMA; DOCETAXEL; SURGERY;

D O I：

10.1016/j.critrevonc.2023.104082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The study aimed to investigate the prognosis and safety of perioperative chemotherapy (PC) compared with adjuvant chemotherapy (AC). Methods: We systematically searched and assessed studies in PubMed, Embase, and the Cochrane Library from inception to 1st September 2022. Results: Eighteen studies were eligible for the analysis, including 4686 patients in total. Our study found that patients with resectable gastric cancer undergoing PC had favorable prognosis on OS (HR 0.77; 95% CI 0.69 -0.87) and DFS (HR 0.76; 95% CI 0.69 -0.84) than those who undergoing AC. Addition of neoadjuvant chemotherapy (NAC) to AC provided higher R0 resection rate but did not increase the risk of postoperative complication rate and most of the adverse event rates. Conclusion: Our study demonstrated that PC shows better OS and DFS in Asians with resectable gastric cancer compared with AC. PC should be preferred because of its favorable prognosis and similar safety.

引用

页数：10

共 44 条

[1] Gastric Cancer, Version 2.2022 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Bentrem, David J. ;

Chao, Joseph ;

Cooke, David ;

Corvera, Carlos ;

Das, Prajnan ;

Enzinger, Peter C. ;

Enzler, Thomas ;

Fanta, Paul ;

Farjah, Farhood ;

Gerdes, Hans ;

Gibson, Michael K. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Keswani, Rajesh N. ;

Kim, Sunnie ;

Kleinberg, Lawrence R. ;

Klempner, Samuel J. ;

Lacy, Jill ;

Ly, Quan P. ;

Matkowskyj, Kristina A. ;

McNamara, Michael ;

Mulcahy, Mary F. ;

Outlaw, Darryl ;

Park, Haeseong ;

Perry, Kyle A. ;

Pimiento, Jose ;

Poultsides, George A. ;

Reznik, Scott ;

Roses, Robert E. ;

Strong, Vivian E. ;

Su, Stacey ;

Wang, Hanlin L. ;

Wiesner, Georgia ;

Willett, Christopher G. ;

Yakoub, Danny ;

Yoon, Harry ;

McMillian, Nicole ;

Pluchino, Lenora A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02) :167-192

[2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[3] Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer [J].

Aoyama, T. ;

Nishikawa, K. ;

Fujitani, K. ;

Tanabe, K. ;

Ito, S. ;

Matsui, T. ;

Miki, A. ;

Nemoto, H. ;

Sakamaki, K. ;

Fukunaga, T. ;

Kimura, Y. ;

Hirabayashi, N. ;

Yoshikawa, T. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1876-1881

[4] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Kim, Young-Woo ;

Yang, Han-Kwang ;

Chung, Hyun Cheol ;

Park, Young-Kyu ;

Lee, Kyung Hee ;

Lee, Keun-Wook ;

Kim, Yong Ho ;

Noh, Sang-Ik ;

Cho, Jae Yong ;

Mok, Young Jae ;

Kim, Yeul Hong ;

Ji, Jiafu ;

Yeh, Ta-Sen ;

Button, Peter ;

Sirzen, Florin ;

Noh, Sung Hoon .

LANCET, 2012, 379 (9813) :315-321

[5] Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years [J].

Cai, Zhaolun ;

Yin, Yuan ;

Shen, Chaoyong ;

Wang, Jian ;

Yin, Xiaonan ;

Chen, Zhixin ;

Zhou, Ye ;

Zhang, Bo .

SURGICAL ONCOLOGY-OXFORD, 2018, 27 (03) :563-574

[6] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

[7]

Ding X W, 2021, Zhonghua Wei Chang Wai Ke Za Zhi, V24, P403, DOI 10.3760/cma.j.cn.441530-20200111-00014

[8] Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19). [J].

Eveno, Clarisse ;

Adenis, Antoine ;

Bouche, Olivier ;

Le Malicot, Karine ;

Hautefeuille, Vincent ;

Faroux, Roger ;

Bidault, Anne Thirot ;

Egreteau, Joelle ;

Meunier, Bernard ;

Mabro, May ;

Carrere, Nicolas ;

Barriere, Nicolas ;

Ben Abdelghani, Meher ;

Mauvais, Francois ;

Di Fiore, Frederic ;

Malka, David ;

Manfredi, Sylvain ;

Piessen, Guillaume .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[9] Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy [J].

Feng, Daofu ;

Leong, Meiha ;

Li, Ting ;

Chen, Lin ;

Li, Tao .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13

[10] Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial [J].

Iwasaki, Yoshiaki ;

Terashima, Masanori ;

Mizusawa, Junki ;

Katayama, Hiroshi ;

Nakamura, Kenichi ;

Katai, Hitoshi ;

Yoshikawa, Takaki ;

Ito, Seiji ;

Kaji, Masahide ;

Kimura, Yutaka ;

Hirao, Motohiro ;

Yamada, Makoto ;

Kurita, Akira ;

Takagi, Masakazu ;

Lee, Sang-Woong ;

Takagane, Akinori ;

Yabusaki, Hiroshi ;

Hihara, Jun ;

Boku, Narikazu ;

Sano, Takeshi ;

Sasako, Mitsuru .

GASTRIC CANCER, 2021, 24 (02) :492-502

← 1 2 3 4 5 →